Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma
Sign Up to like & getrecommendations! Published in 2020 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2020.1611
Abstract: This systematic review and meta-analysis evaluates the immune checkpoint inhibitor regimens used along with the incidence of adverse events reported in randomized clinical trials for treatment of advanced melanoma. read more here.
Keywords: immune checkpoint; advanced melanoma; checkpoint inhibitors; inhibitors immune ... See more keywords
Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016
Sign Up to like & getrecommendations! Published in 2020 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2020.28627
Abstract: Key Points Question When compared with prior therapies, are immune checkpoint inhibitors for metastatic melanoma associated with development of second primary cancers? Findings In this cohort study of 5016 patients with metastatic melanoma between 2005… read more here.
Keywords: immune checkpoint; second primary; primary cancers; checkpoint inhibitors ... See more keywords
Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.26252
Abstract: This systematic review and meta-analysis of randomized clinical trials involving patients with solid tumors assesses the association of immune checkpoint inhibitors with patient-reported quality of life. read more here.
Keywords: inhibitors patient; immune checkpoint; checkpoint inhibitors; clinical trials ... See more keywords
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.52244
Abstract: This comparative effectiveness research study compares outcomes of first-line therapy with immune checkpoint inhibitors vs chemotherapy among patients who have metastatic colorectal cancer with high microsatellite instability, mismatch repair deficiency, and/or high tumor mutational burden. read more here.
Keywords: checkpoint inhibitors; immune checkpoint; metastatic colorectal; inhibitors chemotherapy ... See more keywords
Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.7722
Abstract: Key Points Question What is the association of the use of checkpoint inhibitors with the risk of neurological adverse events? Findings In this meta-analysis of 39 trials evaluating the use of checkpoint inhibitors to treat… read more here.
Keywords: association immune; neurologic adverse; adverse events; checkpoint inhibitors ... See more keywords
Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA neurology"
DOI: 10.1001/jamaneurol.2021.0249
Abstract: Importance Encephalitis is a severe immune-related adverse event secondary to treatment with immune checkpoint inhibitors (ICIs). The spectrum of ICI-induced encephalitis (ICI-iE) ranges from disease that resolves fully to lethal forms. Moreover, ICIs may unmask… read more here.
Keywords: immune checkpoint; checkpoint inhibitors; ici; prognosis ... See more keywords
Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2018.4942
Abstract: Importance Primary resistance to immune checkpoint inhibitors is observed in 10% to 40% of patients with metastatic colorectal cancer (mCRC) displaying microsatellite instability (MSI) or defective mismatch repair (dMMR). Objective To investigate possible mechanisms underlying… read more here.
Keywords: status; immune checkpoint; checkpoint inhibitors; dmmr ... See more keywords
Dynamic changes in circulating tumor DNA assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC
Sign Up to like & getrecommendations! Published in 2023 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13409
Abstract: Immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 axis are the main therapeutic option for patients with advanced non‐small cell lung cancer (NSCLC) without a druggable oncogenic alteration. Nevertheless, only a portion of patients benefit from… read more here.
Keywords: whole genome; checkpoint inhibitors; genome sequencing; benefit ... See more keywords
Time Rules the Efficacy of Immune Checkpoint Inhibitors in Photodynamic Therapy
Sign Up to like & getrecommendations! Published in 2022 at "Advanced Science"
DOI: 10.1002/advs.202200999
Abstract: Lack of adequate effector T cells infiltrated in tumor is one of the main problems in the failure of immune checkpoint blockade therapy (ICBT). Photodynamic therapy (PDT) induced acute inflammation can sensitize tumors and activate… read more here.
Keywords: checkpoint inhibitors; tumor; photodynamic therapy; immune checkpoint ... See more keywords
Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25448
Abstract: Immune checkpoint inhibitors (ICPis) are a novel class of immunotherapeutic agents that have revolutionized the treatment of cancer; however, these drugs can also cause a unique spectrum of autoimmune toxicity. Autoimmune hemolytic anemia (AIHA) is… read more here.
Keywords: immune checkpoint; checkpoint inhibitors; autoimmune hemolytic; hemolytic anemia ... See more keywords
Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4722
Abstract: Anti‐PD1 checkpoint inhibitors (ICI) represent an established standard‐of‐care for patients with recurrent/metastatic head and neck squamous cell carcinoma (RMHNSCC). Landmark studies excluded patients with ECOG performance status (PS) ≥2; the benefit of ICI in this… read more here.
Keywords: head neck; metastatic head; checkpoint inhibitors; performance status ... See more keywords